Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG

NCT04779008 · tracked via the Priya Life Science China tracker

Sponsor

Henan Institute of Cardiovascular Epidemiology

Phase

Not applicable

Started

2021-03-10

Last updated

2025-09-18

Condition(s) studied

Coronary Disease

Investigational drug(s) / intervention(s)

remote ischemic preconditioning （RIPC）

remote ischemic preconditioning （RIPC）: Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.

Study summary

Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Three coronary artery lesions, CABG surgery was planned Exclusion Criteria: * The patients could not tolerate ripc; * peripheral vascular disease affecting upper limbs * Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days, * Emergency cases * Severe structural heart disease and severe arrhythmia ； * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively; * Severe liver, renal and pulmonary disease * Mental disorder can't cooperate; * Inability to give informed consent； * Patients on glibenclamide or nicorandil, as these medications may interfere with RIC * pregnant;

Primary outcome measure(s)

Change of MBF by SPECT — 3 months
Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial blood flow(MBF)
Change of MPR by SPECT — 3 months
Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial perfusion reserve(MPR)
Change of MBF by CE — 3 months
Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial blood flow(MBF)
Change of MPR by CE — 3 months
Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial perfusion reserve(MPR)

Trial sites (1)

Facility	City	Region	Status
Fuwai central China cardiovascular Hospital	Zhengzhou	Henan	Recruiting

More Henan Institute of Cardiovascular Epidemiology trials in China

Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension Starting soon

CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD Recruiting

Influencing Factors and Outcomes of DCB Angioplasty Enrolling by invitation

Prognostic Value of the AMR Measured After PPCI in STEMI Patients Active, not recruiting

Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension Recruiting

Other trials for the same condition

Health Behavior Management Program for Patients With Coronary Heart Disease Enrolling by invitation

Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis Recruiting

Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04779008 on ClinicalTrials.gov ↗ ← All trials in China